Kidney function key to new Drug's safety

NCT ID NCT06496217

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the experimental drug MBX 2109 is handled by the body in people with different levels of kidney function. 25 adults with normal or impaired kidneys received a single dose. The goal was to measure safety and drug levels, not to treat a disease. Results will help decide future doses for patients with kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • MBX Bioscience Investigational Site

    Tampa, Florida, 33603, United States

  • MBX Biosciences Investigational Site

    Miami, Florida, 33136, United States

  • MBX Biosciences Investigational Site

    Minneapolis, Minnesota, 55101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.